Answers are grounded in this paper and cite their sources.
This letter discusses the statistical methodology, specifically the win ratio and Finkelstein-Schoenfeld test, used in a phase 3 trial of acoramidis for transthyretin amyloid cardiomyopathy.
To the Editor: In a phase 3 trial of acoramidis for transthyretin amyloid cardiomyopathy, Gillmore et al. (Jan. 11 issue) 1 used the Finkelstein–Schoenfeld test to assess the hierarchical composite primary outcome. They expressed the treatment effect as a win ratio, thereby following the initial presentation of the analysis of a prioritized outcome. 2 However, the generalized pairwise comparison method, to which the Finkelstein–Schoenfeld test and the win ratio belong, has evolved substantially since this first application. 3 To aid the interpretation of the results, it is now recommended that the proportions of wins and losses for each outcome are reported to understand the . . .
No takes yet. Share an insight, caveat, or question.
A 2024 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: